Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients

Key Points HIV-associated MCD remains a relapsing remitting disease despite rituximab-based therapy. Most patients can be salvaged at relapse by retreating with rituximab, but the risk of developing HHV8-associated lymphomas...